NO885617L - Fremgangsmaate ved paavisning av menneskelig immunsviktvirus - Google Patents

Fremgangsmaate ved paavisning av menneskelig immunsviktvirus

Info

Publication number: NO885617L
Authority: NO; Norway
Prior art keywords: antibodies; antibody; urine; urine sample; immunodeficiency virus
Prior art date: 1987-04-17

Application number

NO885617A

Other languages

English (en)

Norwegian (no)

Other versions

NO885617D0 (no

Inventor

Alvin E Friedman-Kien

Yunzhen Cao

William Borkowsky

Original Assignee

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-04-17

Filing date

1988-12-16

Publication date

1988-12-16

1987-04-17 Priority claimed from US07/040,013 external-priority patent/US4865966A/en

1988-12-16 Application filed by Univ New York filed Critical Univ New York

1988-12-16 Publication of NO885617L publication Critical patent/NO885617L/no

1988-12-16 Publication of NO885617D0 publication Critical patent/NO885617D0/no

Links

238000000034 method Methods 0.000 title claims description 59
241000700605 Viruses Species 0.000 title description 6
210000002700 urine Anatomy 0.000 claims description 79
241000725303 Human immunodeficiency virus Species 0.000 claims description 65
238000002965 ELISA Methods 0.000 claims description 17
238000001262 western blot Methods 0.000 claims description 15
238000001514 detection method Methods 0.000 claims description 12
101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 11
230000003612 virological effect Effects 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 6
230000000951 immunodiffusion Effects 0.000 claims description 5
108010067390 Viral Proteins Proteins 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims 4
239000000523 sample Substances 0.000 description 30
210000002966 serum Anatomy 0.000 description 27
208000030507 AIDS Diseases 0.000 description 19
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
238000003556 assay Methods 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 9
239000013641 positive control Substances 0.000 description 9
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 8
241000283707 Capra Species 0.000 description 8
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000000243 solution Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
101710132601 Capsid protein Proteins 0.000 description 6
238000012286 ELISA Assay Methods 0.000 description 6
239000011324 bead Substances 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000002485 urinary effect Effects 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
230000002860 competitive effect Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
239000013642 negative control Substances 0.000 description 4
230000036963 noncompetitive effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
208000007766 Kaposi sarcoma Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108010015780 Viral Core Proteins Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
235000004252 protein component Nutrition 0.000 description 3
239000000758 substrate Substances 0.000 description 3
JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 2
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
208000004639 AIDS-Related Opportunistic Infections Diseases 0.000 description 2
101710094648 Coat protein Proteins 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
102100034349 Integrase Human genes 0.000 description 2
101710125418 Major capsid protein Proteins 0.000 description 2
101710141454 Nucleoprotein Proteins 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
229940124867 Poliovirus vaccine Drugs 0.000 description 2
101710083689 Probable capsid protein Proteins 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000007792 addition Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000000423 heterosexual effect Effects 0.000 description 2
230000000652 homosexual effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
150000002978 peroxides Chemical class 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000002791 soaking Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
101800001622 120 kDa surface-exposed protein Proteins 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000714195 Aids-associated retrovirus Species 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108010068307 Alpha-Globulins Proteins 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108010087504 Beta-Globulins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
101710174880 Capsid vertex protein Proteins 0.000 description 1
102100028906 Catenin delta-1 Human genes 0.000 description 1
102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
101710099946 DNA mismatch repair protein Msh6 Proteins 0.000 description 1
102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 1
101710113614 DNA primase small subunit PriS Proteins 0.000 description 1
238000011891 EIA kit Methods 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101710104359 F protein Proteins 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
206010024227 Lepromatous leprosy Diseases 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
241001077660 Molo Species 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000007982 barbital buffer Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012468 concentrated sample Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
201000011200 hepatorenal syndrome Diseases 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
238000011034 membrane dialysis Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO885617A 1987-04-17 1988-12-16 Fremgangsmaate ved paavisning av menneskelig immunsviktvirus NO885617D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/040,013 US4865966A (en)	1987-04-17	1987-04-17	Method for detecting antibodies to human immunodeficiency virus
PCT/US1988/001304 WO1988008039A1 (fr)	1987-04-17	1988-04-15	Procede de detection d'anticorps dresses contre le virus de l'immunodeficience humaine

Publications (2)

Publication Number	Publication Date
NO885617L true NO885617L (no)	1988-12-16
NO885617D0 NO885617D0 (no)	1988-12-16

Family

ID=26716652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO885617A NO885617D0 (no)	1987-04-17	1988-12-16	Fremgangsmaate ved paavisning av menneskelig immunsviktvirus

Country Status (4)

Country	Link
DK (1)	DK697188A (fr)
MC (1)	MC2013A1 (fr)
MW (1)	MW5888A1 (fr)
NO (1)	NO885617D0 (fr)

1988
- 1988-04-15 MC MC88US8801304D patent/MC2013A1/fr unknown
- 1988-12-12 MW MW5888A patent/MW5888A1/xx unknown
- 1988-12-15 DK DK697188A patent/DK697188A/da not_active Application Discontinuation
- 1988-12-16 NO NO885617A patent/NO885617D0/no unknown

Also Published As

Publication number	Publication date
DK697188D0 (da)	1988-12-15
NO885617D0 (no)	1988-12-16
MC2013A1 (fr)	1990-02-16
MW5888A1 (en)	1989-06-14
DK697188A (da)	1989-02-16

Publication	Publication Date	Title
EP0216191B1 (fr)	1991-06-19	Essai immunologique pour antigènes de HTLV-III
Grauballe et al.	1981	Optimized enzyme‐linked immunosorbent assay for detection of human and bovine rotavirus in stools: Comparison with electron‐microscopy, immunoelectro‐osmophoresis, and fluorescent antibody techniques
Mabey et al.	1988	Human retroviral infections in The Gambia: prevalence and clinical features
Simmonds et al.	1988	HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort
US5122446A (en)	1992-06-16	Method for detecting antibodies to human immunodeficiency virus
US20030180313A1 (en)	2003-09-25	EIA test using nondenatured HIV antigen for early detection of HIV infection
US4865966A (en)	1989-09-12	Method for detecting antibodies to human immunodeficiency virus
CA1305411C (fr)	1992-07-21	Methode de determination des anticorps anti-vih, et application de la methode
Treanor et al.	1988	Development of an enzyme immunoassay for the Hawaii agent of viral gastroenteritis
Rinaldo et al.	1989	Association of human immunodeficiency virus (HIV) p24 antigenemia with decrease in CD4+ lymphocytes and onset of acquired immunodeficiency syndrome during the early phase of HIV infection
EP0196873B1 (fr)	1989-12-13	Diagnostic pour micro-organismes
Handsher et al.	1977	Modified staphylococcal absorption method used for detecting rubella-specific immunoglobulin M antibodies during a rubella epidemic
Goudsmit et al.	1987	Circulation of HIV antigen in blood according to stage of infection, risk group, age and geographic origin
Cumming et al.	1990	Use of a conserved immunodominant epitope of HIV surface glycoprotein gp41 in the detection of
Cot et al.	1988	Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis
US6872396B2 (en)	2005-03-29	Specificity in the detection of anti-rubella IGM antibodies
US4879211A (en)	1989-11-07	Rapid immunoagglutination test for presence of HIV in body fluids
KR960005366B1 (ko)	1996-04-24	후천성 면역결핍 증후군(aids) 관련 바이러스에 대한 항체 검출용 시약
RU2032907C1 (ru)	1995-04-10	Способ определения антител к вирусу иммунодефицита человека
Martin et al.	1992	A screening test for the detection of anti-HIV-1 IgA in young infants
EP0495465A2 (fr)	1992-07-22	Essai immuno-enzymatique pour détecter des anticorps virales
KR910004213B1 (ko)	1991-06-24	Atlv 항체의 측정시약 및 측정방법
CN119104732A (zh)	2024-12-10	一种高敏感性和高特异性的血清SARS-CoV-2 IgM和IgG抗体检测方法
Acaye et al.	1995	Evaluation of performance of reused HIVCHEK 1+ 2 test blocks which have shown negative result: a reliable method for rural hospital?
EP0445650A2 (fr)	1991-09-11	Détection d'anticorps anti-VIH